Kaken Pharmaceutical Co., Ltd.
February 1, 2019 – Kaken Pharmaceutical Co., Ltd. (“Kaken”, head office Bunkyo-ku, Tokyo) and TIPR-HUYA Advancing Innovative Medicines (“AIM”, head office Tianjin, People’s Republic of China) announced today that Kaken has concluded an exclusive license and distribution agreement for the topical formulation for Onychomycosis “Clenafin / Jublia” (“Product”) in the People’s Republic of China (“PRC”)
The Product contains efinaconazole, which is new triazole anti-fungal compound discovered by Kaken, as the active ingredient. Efinaconazole has low binding affinity with keratin, the main component of nails, meaning that the Product has superior nail-penetrating properties.
The Product was launched under the trade name of Clenafin in Japan by Kaken in 2014. Overseas, the Product was launched under the trade name of Jublia, in the United States and Canada by Bausch Health Companies Inc. in 2014 and in Korea by Dong-A ST Co., Ltd. in 2017.
According to the agreement, Kaken hereby grants AIM the exclusive right for the development and commercialization of the Product in PRC.
Under the agreement, Kaken receives an upfront cash payment and has the potential to receive milestone payments and royalties on the net sales of the Product.
AIM is the joint venture between HUYA Bioscience and the Tianjin Institute of Pharmaceutical Research, TIPR. AIM identifies and evaluates medical opportunities both within and outside China. It utilizes TIPR’s infrastructure in China and HUYA’s global network to accelerate the development of products for both the Chinese and global markets. HUYA and TIPR share equally in decision-making regarding product development and commercialization.